Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 12/20 | 0.46 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | PLTP | P55058 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12839329 | 0.94 | TRPV1 (0.48) | HCAR2TOP2ATOP2BMAPK14PLTP | |
| SCHEMBL12839298 | 0.94 | MAPK14 (0.45) | HCAR2MAPK14LMNAKMT2AMAPT | |
| SCHEMBL12840580 | 0.92 | HCAR2 (0.48) | HCAR2TOP2ATOP2BMAPK14PLTP | |
| SCHEMBL12839338 | 0.90 | MAPK14 (0.41) | MAPK14KMT2A | |
| SCHEMBL13068114 | 0.89 | HCAR2 (0.49) | HCAR2TOP2ATOP2BMAPK14LMNA | |
| SCHEMBL12840708 | 0.89 | HCAR2 (0.42) | HCAR2TOP2ATOP2BMAPK14PLTP | |
| SCHEMBL12838677 | 0.89 | POLB (0.45) | HCAR2TOP2ATOP2BMAPK14PLTP | |
| SCHEMBL12839299 | 0.88 | HDAC1 (0.44) | MAPK14TRPV1KMT2A | |
| SCHEMBL12839103 | 0.87 | CCNE1 (0.41) | MAPK14KMT2AMAPTHTT | |
| SCHEMBL12840558 | 0.87 | TRPV1 (0.47) | HCAR2TOP2ATOP2BPLTPCYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110070656-A1 | Fluorescent Proteins | JNC CORPORATION (JP) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070656-A1 | Fluorescent Proteins | CACYBP, CHLSN, LCP2 | HCAR2 3839/4885TOP2A 3075/4885TOP2B 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.